Riociguat

證據等級: L5

預測適應症: 0 個

Riociguat: Evaluation Incomplete — Insufficient Data for Repurposing Analysis

One-Sentence Summary

Riociguat (DrugBank ID: DB08931) has been identified as a candidate for drug repurposing evaluation. However, the current Evidence Pack contains no TxGNN-predicted indications, no original indication records, and no safety data, making it impossible to conduct a meaningful mechanistic or clinical evidence assessment at this stage.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	No TxGNN predictions generated
TxGNN Prediction Score	N/A
Evidence Level	Not assessable
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why No Assessment Is Possible

The Evidence Pack for Riociguat is missing three critical data categories:

1. No original indication data The original_indications field is empty, and no approved product label (package insert) data has been parsed into structured form. Without knowing the drug's approved therapeutic context, mechanistic bridging to a new indication cannot be attempted.

2. No mechanism of action (MOA) MOA data is flagged as a high-severity gap (DG002). Without knowing how Riociguat exerts its pharmacological effect, it is not possible to reason about mechanistic applicability to other diseases.

3. No TxGNN predictions The predicted_indications array is empty. This means the TxGNN knowledge-graph model either has not yet processed this drug, or the drug did not pass the minimum score threshold to generate candidate indications. Until predictions are generated, no evidence review can proceed.

Safety Considerations

Please refer to the package insert for safety information.

Note: A package insert query (tfda_package_insert) was executed on 2026-03-29 with status success, indicating source material exists. However, structured safety fields (warnings, contraindications, DDI) have not been parsed from this source into the Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: There are currently no TxGNN-predicted indications and no structured drug-level data available; proceeding to any stage of repurposing analysis would be premature and methodologically unsound.

To proceed, the following is needed:

Parse the package insert — The tfda_package_insert query returned one result (2026-03-29). Extract and structure the approved indications, warnings, and contraindications from this document into the Evidence Pack.
Retrieve MOA from DrugBank — DrugBank query returned one result (result_count: 1). Extract the mechanism of action, pharmacological class, and drug categories to populate original_moa.
Re-run TxGNN prediction pipeline — Once drug-level metadata is populated, re-submit Riociguat to the TxGNN model to generate scored indication candidates.
Re-run DDI query — The current DDI query returned not_found. After MOA and drug class are confirmed, re-query the DDI database with enriched drug profile parameters.
Generate updated Evidence Pack (v5) — Only after steps 1–4 are complete should a full evaluation report be generated.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.